News
Directorate Change
30 March 2012
TyraTech, Inc. (AIM: TYR), a natural life sciences company, announces that, Dr. Kevin Schultz, the Company's Chief Scientific Officer, will step down from his current role at the Company with effect from 1 April 2012 and will be appointed as a Non-Executive Director of the Company with effect from 1 April 2012.
Prior to joining TyraTech in August 2010, Dr. Schultz held numerous executive level positions with leading animal health organizations, including Merck & Co., Inc and Merial Limited where he was Chief Scientific Officer. Dr. Schultz received his Doctor of Veterinary Medicine from Purdue University and earned a Ph.D. from the University of Florida Medical School before joining Harvard Medical School and Harvard School of Public Health as a Fellow in Cancer Biology. Dr Schultz is a Venture Fellow for the Georgia Research Alliance.
All research and development activities for the Company will now be under the oversight of Dr. Keith Kennedy, Vice President Product Development.
Alan Reade, Executive Chairman of the Company, commented:
"We would like to thank Kevin for his time as TyraTech's Chief Scientific Officer and we are pleased to welcome him onto the Board. Kevin has a wealth of experience and expertise in the life sciences sector which we are delighted to be able to continue to draw upon."
Dr. Kevin Thomas Schultz, aged 60, does not currently hold, nor has held in the past five years, any other directorships.
Dr. Schultz holds a total of 200,000 Stock Appreciation Rights over common shares in the Company with a par value of US$0.001.
There is no other information regarding Dr. Schultz that is required to be disclosed pursuant to Schedule 2 (g) of the AIM Rules for Companies.
For further information please contact:
TyraTech Inc.
Alan Reade, Executive Chairman
Tel: +1 919 415 4310
Peter Jerome, Chief Financial Officer
Tel: +1 919 415 4280
N+1 Brewin, Nominated Adviser and Joint Broker
Aubrey Powell/ Robert Beenstock
Tel: +44 20 3201 3170
First Columbus LLP, Joint Broker
Chris Crawford
Tel: 020 3002 2070
Disclaimer for U.S. Site Visitors
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.